Research Article

Portal Vein Stenting Combined with 125I Particle Chain Implantation Followed by As2O3 in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumour Thrombus

Table 3

Adverse events related to procedure.

Adverse eventAll eventsGrade of toxicity CTCAE
12≥3

Fever7 (23.3%)4 (13.3%)3 (10%)0
Hemorrhage3 (10%)2 (6.7%)1 (3.3%)0
Stent or seeds migration0000
Abdominal pain3 (10%)1 (3.3%)2 (6.7%)0
RILD0000
Leukopenia1 (3.3%)1 (3.3%)00
Gastrointestinal ulceration0000
Total14 (46.7%)7 (23.3%)6 (20%)0

Note: data are number of patients (%); RILD = radiation-induced liver disease. Adverse events were assessed after 1 week of procedure.